Mounjaro®
Starting from £179.99/mo
Start journey Learn moreWegovy does not produce noticeable weight loss straight away. Most people begin their first 0.25 mg dose and feel little change for several weeks — that is completely expected. The medicine is working at a hormonal level from the first injection, but visible results take time to build. Here is what actually happens, and when.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The most common misunderstanding about Wegovy is that silence equals failure. People start the 0.25 mg dose, notice they are not dramatically less hungry, and wonder whether something has gone wrong. Nothing has gone wrong. The starting dose is not designed to produce significant appetite suppression, its job is to let your digestive system adjust to semaglutide before the dose climbs. Most of the gastrointestinal side effects people worry about (nausea, loose stools, indigestion) are related to dose level; beginning low reduces the chance of them hitting hard. So if week one feels almost ordinary, that is the point.
The titration schedule for Wegovy moves through 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg and up to 2.4 mg, each step held for roughly four weeks. The appetite-reducing effect deepens at each rung. If you are curious about whether Wegovy works straight away, the titration schedule helps explain why the process takes time rather than delivering immediate results. The process is running; the output takes time.
The NHS medicines page for semaglutide confirms that weight loss with Wegovy is gradual and is achieved alongside a reduced-calorie diet and increased physical activity, not separately from them.
Appetite tends to change in a meaningful way once the dose reaches 1.0 mg or above, which for most people is around weeks nine to twelve of treatment. That is when the medicine is working at a level closer to its therapeutic effect. Some people notice hunger dropping sooner; others need the higher doses to feel much difference. Both are normal, individual response to GLP-1 medicines varies considerably.
Actual scale movement tends to lag behind the appetite shift by another few weeks, because weight loss requires a sustained calorie deficit to accumulate. If you are wondering when Wegovy starts working specifically for weight loss, the honest answer for most people is: meaningfully, from around months two to four, with the steepest progress typically between months four and twelve. The STEP 1 trial, published in the New England Journal of Medicine, tracked participants over 68 weeks, weight loss was not a sprint; it was a long, consistent arc.
One practical note on timing: if you are starting around a holiday, a busy travel period or a week when routine is disrupted, your prescriber can advise whether it is worth delaying. Consistency in eating habits, sleep and activity all support the medicine's effect, and understanding how to store Wegovy correctly is another practical step that helps maintain that consistency, so a stable fortnight at the start helps.
Paradoxically, some of the earliest signals that Wegovy is doing something are not weight-related at all, they are gastrointestinal. Nausea, a feeling of fullness after small meals, or mild reflux in the first days after a dose increase are common, especially as the schedule climbs. These typically ease within a week or two as the body adjusts. Many people ask whether Wegovy starts working right away, and these early gut signals are often the first indication that the medicine is interacting with receptors as intended, even before appetite or weight changes become obvious.
More serious symptoms require prompt attention. Severe stomach pain that spreads to the back, with or without vomiting, should be assessed urgently, the MHRA highlighted acute pancreatitis as a known, infrequent but serious risk for GLP-1 medicines in a Drug Safety Update published January 2026. Gallbladder symptoms, significant dehydration from persistent vomiting, or signs of an allergic reaction also warrant same-day medical contact. Any suspected side effects can be reported through the MHRA Yellow Card scheme.
The fuller picture of semaglutide's side-effect profile is covered in detail on our Wegovy information page, and a prescriber will walk through what to watch for before you start.
Several factors shape how quickly and clearly someone responds. Dose level matters most, but so does consistency: Wegovy works best when taken on the same day each week, at the highest tolerated dose, alongside genuine changes to eating patterns and activity. Missing doses or frequently shifting your injection day slows the process.
Starting weight, metabolic factors and whether any weight-related conditions are present also influence the trajectory. A person with higher starting BMI may see a larger absolute reduction in kilograms early on while the percentage change builds steadily. There is no shortcut formula, which is exactly why the prescriber reviews progress before each dose increase rather than leaving titration to guesswork.
If you are weighing up which treatment approach suits your situation, or thinking about the private cost involved, our Wegovy pricing page sets out what is included in a legitimate private prescription. Treatment through a registered pharmacy requires a clinical assessment first, a prescriber at nume reviews every consultation personally before any medicine is dispensed. Whenever you are ready, you can speak to our prescribers to find out whether Wegovy is clinically suitable for you.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.